Concord Biotech Ltd. (CONCORDBIO) Price & Analysis

Compare

2 Followers

CONCORDBIO Stock Chart & Stats

₹1338.60

₹62.10(2.74%)

At close: Jan 09 4:00 PM EST

₹1338.60

₹62.10(2.74%)

Day’s Range― - ―

52-Week Range₹1,092.30 - ₹2,149.90

Previous CloseN/A

Volume295.44K

Average Volume (3M)12.81K

Market Cap

₹120.24B

Enterprise Value₹114.70B

Total Cash (Recent Filing)₹3.18B

Total Debt (Recent Filing)₹0.00

Price to Earnings (P/E)38.5

Beta1.20

Next Earnings

May 21, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield0.8%

Share Statistics

EPS (TTM)6.30

Shares Outstanding104,616,200

10 Day Avg. Volume31,605

30 Day Avg. Volume12,808

Financial Highlights & Ratios

PEG Ratio2.27

Price to Book (P/B)9.60

Price to Sales (P/S)14.50

P/FCF Ratio127.69

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage / Strong Balance SheetA low debt-to-equity structure reduces default and refinancing risk, giving management lasting financial flexibility to fund capacity, meet regulatory compliance, and invest in process scale-ups without reliance on expensive external financing. This supports long-term operational resilience and strategic optionality.

Consistent Revenue And ProfitabilitySustained revenue growth combined with healthy gross and net margins points to durable competitiveness in complex fermentation-based APIs. Consistent profitability signals effective cost control and pricing power, enabling reinvestment in R&D and capacity that underpin multi-quarter to multi-year growth trajectories.

Positive Operating Cash GenerationReliable operating cash generation provides a durable source of funding for capex, working capital and scale-up projects, lowering reliance on external capital. Strong cash conversion enhances the firm’s ability to sustain manufacturing investments and absorb cyclical variations in API demand over several quarters.

Bears Say

Inconsistent Free Cash Flow GrowthVolatility in free cash flow growth creates uncertainty around the company’s capacity to consistently fund capital expenditures, process upgrades and partner commitments. This uneven FCF profile can force timing variability in investments or increase reliance on short-term financing, weakening long-term execution certainty.

Slight Gross Margin PressureA declining gross margin, even if modest, suggests rising input or processing costs or pricing pressure in API markets. If sustained, margin erosion reduces reinvestment headroom, constrains competitive pricing flexibility for long-term contracts, and can impair the durability of current profitability levels.

Negative EPS Growth TrendA negative EPS growth rate indicates per-share earnings have trended down, which can reflect margin compression, cost variability or dilution. Persisting EPS decline undermines long-term per-share value, limits dividend or buyback capacity, and can constrain strategic investments over multiple quarters.

Concord Biotech Ltd. News

Concord Biotech Updates Key Managerial Authorisations for Market Disclosures

Concord Biotech Ltd. ( ($IN:CONCORDBIO) ) has shared an announcement. Concord Biotech Limited has revised the list of...

2M ago

Mycophenolate Pregnancy Registry: Key Insights for Investors

Amneal Pharma (($AMRX)), Sandoz Group Ltd (($SDZXF)), Alkem Laboratories Ltd. (($IN:ALKEM)), Concord Biotech Ltd. (($IN:CONCORDBIO)) announced an update...

4M ago

AMRX

Concord Biotech Releases Q1 2025 Financial Results

Concord Biotech Ltd. ( ($IN:CONCORDBIO) ) has issued an update. Concord Biotech Ltd. has released an investor presentation...

7M ago

Concord Biotech Releases Q3 2025 Earnings Call Transcripts

Concord Biotech Ltd. ( ($IN:CONCORDBIO) ) just unveiled an announcement. Concord Biotech Limited has made available the transcripts...

1y ago

CONCORDBIO FAQ

What was Concord Biotech Ltd.’s price range in the past 12 months?

Concord Biotech Ltd. lowest stock price was ₹1092.30 and its highest was ₹2149.90 in the past 12 months.

What is Concord Biotech Ltd.’s market cap?

Concord Biotech Ltd.’s market cap is ₹120.24B.

When is Concord Biotech Ltd.’s upcoming earnings report date?

Concord Biotech Ltd.’s upcoming earnings report date is May 21, 2026 which is in 87 days.

How were Concord Biotech Ltd.’s earnings last quarter?

Concord Biotech Ltd. released its earnings results on Feb 11, 2026. The company reported ₹6.3 earnings per share for the quarter, missing the consensus estimate of ₹7.2 by -₹0.9.

Is Concord Biotech Ltd. overvalued?

According to Wall Street analysts Concord Biotech Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Concord Biotech Ltd. pay dividends?

Concord Biotech Ltd. pays a Notavailable dividend of ₹10.7 which represents an annual dividend yield of 0.8%. See more information on Concord Biotech Ltd. dividends here

What is Concord Biotech Ltd.’s EPS estimate?

Concord Biotech Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Concord Biotech Ltd. have?

Concord Biotech Ltd. has 104,616,200 shares outstanding.

What happened to Concord Biotech Ltd.’s price movement after its last earnings report?

Concord Biotech Ltd. reported an EPS of ₹6.3 in its last earnings report, missing expectations of ₹7.2. Following the earnings report the stock price went down -3.042%.

Which hedge fund is a major shareholder of Concord Biotech Ltd.?

Currently, no hedge funds are holding shares in IN:CONCORDBIO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Concord Biotech Ltd.

Concord Biotech Limited, a biopharma company, engages in the research and development, manufacturing, marketing, and sale of pharmaceutical products in India and internationally. It provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. The company also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, and pimecrolimus for immunosuppressants therapeutic segment; temsirolimus, everolimus, romidepsin, mitomycin, midostaurin, and dactinomycin for oncology therapeutic segment; mupirocin, mupirocin calcium, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, and micafungin sodium for anti-fungal therapeutic segment; and lovastatin and pravastatin sodium for other applications. In addition, it provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.